NCT01263951

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Thomas Jefferson University · Academic / Other
• Sex: All
• Age: 18 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.

Detailed description

The purpose of this research study is to: 1. Find out if sorafenib and everolimus prevent the growth of tumors that have grown when treated with sorafenib alone 2. Find out how long one might benefit from treatment with sorafenib and everolimus 3. Find out what side effects this drug may cause 4. Measure the amount of sorafenib and everolimus in the blood and see if "markers" can be found to help understand who might benefit from sorafenib and everolimus.

Conditions

• Differentiated Thyroid Cancer

Interventions

Type	Name	Description
DRUG	Everolimus	One 5 mg. tablet daily.
DRUG	Sorafenib	200 mg. twice daily.

Timeline

• Start date: 2010-11-01
• Primary completion: 2021-02-01
• Completion: 2022-05-01
• First posted: 2010-12-21
• Last updated: 2021-10-26

Locations

1 site across 1 country: United States